Meeting Program and Abstracts
2019; Mary Ann Liebert, Inc.; Volume: 29; Issue: s1 Linguagem: Inglês
10.1089/thy.2019.29085.abstracts
ISSN1557-9077
AutoresMaria Papaleontiou, Sarah J. Peterson, X. S. Ding, Ying Yang, Connie Meeyoung, Rhee Charles, Andrew Carter, Rebecca S. Bahn, Deborah Doniach, Gabriella Morreale de Escobar, Panel Discussion, Elizabeth Pearce, Sandra M. McLachlan, Juan Bernal, Robin P. Peeters, Anthony N. Hollenberg, Marco Medici, Rossella Elisei, J. Woody Sistrunk, George J. Kahaly, Chrysoula Dosiou, Marius N. Stan, Antonio Di Cristofano, Mona M. Sabra, Bryan R. Haugen, Terry J. Fry, Silvia Ippolito, Raffaele Ciampi, Ana-Maria Chindris, Eva Katrin, W E Paul, Michael T. Yen, László Hegedűs, Fulvio Basolo, Lin Yansong, Anastasios Maniakas, Rosa Falcone, Leonard Wartofsky, Francesco S. Celi, Ernest Asamoah, Charles W. Carter, Minjing Zou, Huda A. BinEssa, Yousif H. Al-Malki, Ibrahim Al‐Jammaz, Anwar F Al-Enezi, Falah Almohanna, Abdullah M. Assiri, Brian F. Meyer, Ali S. Alzahrani, Yuxiang Shi, Travis A. Smith, Saba Sile, Elizabeth L. Thompson, Thomas Vescio, Renee Perdok, Jeffrey W. Sherman, Raymond S. Douglas, Xia Yin, Xujun Liang, Kelly‐Anne Phillips, Susanne Neumann, Shuja Shafi Malik, Bernice Marcus‐Samuels, Е. В. Елисеева, D. Jang, Joanna Kłubo-Gwieździńska, Cornelia Krieger, Marvin C. Gershengorn, David Reyes‐Gastelum, Mousumi Banerjee, Sarah T. Hawley, Megan R. Haymart, Thaís C. O. Fonseca, Kathryn G. Schuff, Elizabeth A. McAninch,
ResumoThyroidVol. 29, No. s1 89th Annual Meeting of the American Thyroid AssociationFree AccessMeeting Program and AbstractsOctober 30—November 3, 2019 Sheraton Grand Chicago Chicago, IllinoisPublished Online:29 Oct 2019https://doi.org/10.1089/thy.2019.29085.abstractsAboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail 89th ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION® WEDNESDAY, OCTOBER 30, 20196:00 AM – 6:00 PMATA Speaker Ready Room (Open to meeting faculty only) 6:00 AM – 7:30 PMATA Registration Open 7:00 AM – 4:30 PMATA Endocrine Neck Ultrasound Course (Satellite program, separate registration required) 8:00 AM – 2:00 PMATA Board of Directors Meeting (by invitation only) 12:00 PM – 6:30 PMATA Exhibit Hall (Open for Exhibitor Setup Only) 8:00 AM – 11:15 AME. Chester Ridgway Trainee Day Morning Symposium - Combined Clinical and Basic Sessions (Ticketed event; open to all attendees; complimentary to trainees with pre-registration)(See Trainees Agenda)11:15 AM – 12:50 PMRidgway Trainee Day Lunch Roundtable Discussions (Pre-registration required)(See Trainees Agenda)1:00 PM – 3:40 PMRidgway Trainee Day Basic Afternoon Breakout Symposium (Open to all pre-registered trainees and paying non-trainees)(See Trainees Agenda)1:00 PM – 3:40 PMRidgway Trainee Day Clinical Afternoon Breakout Symposium (Open to all pre-registered trainees and paying non-trainees)(See Trainees Agenda)2:45 PM – 4:00 PMATA Committee and Task Force Meetings (Open to 2018–2019 ATA Committee and Task Force members only) 5:00 PM – 5:15 PMATA Welcome Remarks and Strategic Goals Update Victor J. Bernet, MD, ATA Secretary/COOJacqueline Jonklaas, MD, ATA Secretary/COO-Elect 5:15 PM – 5:25 PMWelcome to the 89th Annual Meeting of the ATAElizabeth N. Pearce, MD, ATA PresidentVictor J. Bernet, MD, ATA Secretary/COOJacqueline Jonklaas, MD, ATA Secretary/COO-ElectAntonio Di Cristofano, PhD, Program Committee Co-ChairMona M. Sabra, MD, Program Committee Co-Chair 5:25 PM – 6:45 PMOpening Session: Recent Developments and Future Challenges in ThyroidologyCo-Chairs: Antonio Di Cristofano and Mona M. SabraClinical ReviewBasic ReviewSurgical ReviewNaifa Lamki BusaidySheue-yann ChengMichael W. Yeh6:45 PM – 7:45 PMATA Opening Welcome Reception in the Exhibit Hall (Meeting registration/badge required for entry) 89th ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION® THURSDAY, OCTOBER 31, 20196:00 AM – 5:30 PMATA Registration Open 6:00 AM – 6:00 PMATA Media Room (Open to press/media only) 6:00 AM – 6:00 PMATA Speaker Ready Room (Open to meeting faculty only) 7:00 AM – 8:00 AMATA Women in Thyroidology (WIT) Program and Business Meeting: Promotions and Leadership Development (Pre-registration requested; first-come, first served)Sissy M. JhiangJulie Ann SosaAnthony N. Hollenberg8:00 AM – 8:05 AMMorning Announcements and Welcome to the 89th Annual MeetingElizabeth N. Pearce, MD, ATA PresidentVictor J. Bernet, MD, ATA Secretary/COOAntonio Di Cristofano, PhD, Program Committee Co-ChairMona M. Sabra, MD, Program Committee Co-Chair 8:05 AM – 8:50 AMVan Meter Award Lecture (Awardee announced onsite at time of lecture) 8:50 AM – 10:00 AMRidgway Trainee Conference: Case Discussions – Thyroid Nodules and Thyroid Cancer (Open to all trainees)(See Trainees Agenda)8:50 AM – 10:05 AMHighlighted Oral Abstracts SessionCo-Chairs: Antonio Di Cristofano and Mona M. SabraOral Abstract 1: Attenuation of Ctnnb 1 Inhibits Progression of BrafV600E- Induced Papillary Thyroid Cancer and Promotes Re-Differentiation and Iodine UptakeOral Abstract 2: Efficacy of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor Antagonist Antibody, in Patients with Active Thyroid Eye Disease: Pooled Results from Two Placebo-Controlled TrialsOral Abstract 3: Effect of Intraventricular Chronic Injection of Thyroid Hormone on Energy Metabolism in MiceOral Abstract 4: Heat-Inducible Mesenchymal Stem Cell (MSC)-Mediated Sodium Iodide Symporter (NIS) Gene TherapyOral Abstract 5: Do Molecular Profiles of Primary versus Metastatic Radioiodine Refractory Differentiated Thyroid Cancer Differ?Yufei ShiGeorge J. KahalyLiangchun CaiMariella TutterCristiane J. Gomes Lima10:00 AM – 4:30 PMExhibit and Poster Hall Open (Open at 8:00 AM to poster presenters and exhibitors only) 10:05 AM – 11:00 AMPoster Review Session and Break in the Exhibit Hall 10:05 AM – 11:00 AMAdvanced Clinical Conversations in Hypothyroidism: Expo Theater Presented by AbbVie Inc. (Limited seating; first-come, first served)Todd W. Frieze11:00 AM – 12:15 PMBasic Symposium: Thyroid Hormone-Mediated Regulation of Cell Proliferation and DifferentiationChair: Mabel M. RyderThe Role of Thyroid Hormones in Mammal NeurogenesisThyroid Hormone Mediated Control of the Balance Between the Proliferation and DifferentiationMembrane Receptors for Thyroid Hormones: Roles in CancerSylvie RemaudMonica DenticeOsnat Ashur-Fabian11:00 AM – 12:15 PMClinical Symposium: Iodine and HealthCo-Chairs: Angela M. Leung and Elizabeth N. PearceEliminating Iodine Deficiency - The EUthyroid projectNew Insights into the Mechanism of NISIodine Status in LactationHenry VölzkeNancy CarrascoTim Korevaar12:15 PM – 1:30 PMPoster Review Session and Break in the Exhibit Hall/ Lunch on your Own 12:30 PM – 1:25 PMKeys to Identifying and Co-managing Thyroid Eye Disease (TED): Insights from an Endocrinologist and an Oculoplastic Surgeon: Expo Theater Presented by Horizon Therapeutics (Lunch provided; Limited seating; first-come, first served)Terry J. SmithRaymond S. Douglas12:30 PM – 1:30 PMRidgway Trainee Conference: All Trainees Lunch Session – Grant Writing (Open and complimentary to all trainees; Lunch ticket required for meal)(See Trainees Agenda)1:30 PM – 2:15 PMPaul Starr Award Lecture: Low-Risk Thyroid Cancer. Evidence, Expert Opinion, and Common SenseIntroduction by Gilbert H. DanielsDouglas S. Ross2:15 PM – 4:25 PMRidgway Trainee Conference: Introductory Thyroid Ultrasound Course (Note: This course is extremely basic. The main goal of this course is introducing the basics of diagnostic thyroid ultrasound to trainees with no experience at all)(See Trainees Agenda)2:20 PM – 3:50 PMBasic/ Translational Abstracts: Thyroid Hormones in Metabolism and DevelopmentCo-Chairs: Arturo Hernandez and Kevin J. PhillipsOral Abstract 6: Diminished Serum T4 Concentrations Induced by PTU or Brominated Flame Retardants (DE-71) are Necessary But Not Sufficient for a Congenital Malformation of the BrainOral Abstract 7: Generation and Transplantation of hiPSC-Derived Thyroid Follicular CellsOral Abstract 8: A Remarkable Stem Cell Surge During Mouse Thyroid RegenerationOral Abstract 9: TR Activation Elicits White to Beige Transdifferentiation Independent of β-Adrenergic SignalingOral Abstract 10: Thyrotropin Causes Dose-dependent Biphasic Regulation of cAMP Production Mediated by Gs and Gi/o ProteinsOral Abstract 11: The Dio2-Dependent Gene Zfp125 Inhibits Ketogenesis and Stimulates Gluconeogenesis in LiverLouise RamhøjHendrik Julian UndeutschRisheng MaYan XiaSusanne E. NeumannGustavo Werpel Fernandes2:20 PM – 3:50 PMClinical Abstracts: Thyroid Hormone ActionCo-Chairs: Haixia Guan and Mary H. SamuelsOral Abstract 12: Understanding the Risks of Thyroid Hormone Replacement: Is there a Relationship between TSH Level and Atrial Fibrillation and Stroke?Oral Abstract 13: Effect of Thr92Ala-DIO2 Polymorphism on Cognition, Mood and Health Status Among LT4 Treated Hypothyroid IndividualsOral Abstract 14: Low Serum Free Thyroxine Levels Are Associated with Metabolic Syndrome in a Euthyroid Healthy Population: A Retrospective Cohort Study in Shaanxi Province, ChinaOral Abstract 15: Preconception Thyroid Stimulating Hormone Level and Risk of Preterm Birth in Over 4.3 Million Rural Chinese Women Aged 20–49 Years: A Population-Based Cohort StudyOral Abstract 16: Examining the Interrelationship Between Serum Thyrotropin Levels and Kidney Disease in the National OptumLabs Data WarehouseOral Abstract 17: Stability and Consistency of Compounded Oral Liquid Formulations of LevothyroxineMaria PapaleontiouSarah J. PetersonXi DingYing YangConnie Meeyoung RheeCharles A. Carter3:50 PM – 4:15 PMExhibitor Networking and Break in the Exhibit Hall 4:15 PM – 5:05 PMClark T. Sawin Historical Vignette Women in Thyroidology: The Power of Scientific Kangaroo Leaps – Paradigm Shifting Scientific ContributionsModerator and Introduction: Rebecca S. BahnDeborah DoniachGabriella Morreale de EscobarPanel DiscussionRebecca S. BahnElizabeth N. PearceSandra M. McLachlanJuan Bernal5:10 PM – 6:00 PMDiscussion-Debates/Meet the Professor Workshops (First-come, first-served) 5:10 PM – 6:00 PMDD/MTP 1: Thyroid Hormone Function: Aging and GeneticsModerator: Robin P. PeetersAnthony N. HollenbergMarco Medici5:10 PM – 6:00 PMDD/MTP 2: Systemic Therapy in Medullary Thyroid CancerModerator: Rossella EliseiNaifa Lamki BusaidyMabel M. RyderBruce G. RobinsonLori J. Wirth5:10 PM – 6:00 PMDD/MTP 3: Remote Access Thyroid Surgery Update 2019: When? Why? How?Moderator: Ralph P. TufanoHoon Yub KimVictoria E. BanuchiEmad Kandil5:10 PM – 6:00 PMDD/MTP 4: Genetics and Genomics Applied To Cancer/Molecular Prognostics and TherapeuticsModerator: Bryan McIverYuri NikiforovSebastiano FilettiMingzhao Xing5:10 PM – 6:00 PMDD/MTP 5: High Activity RAI Therapy: Effect on Fertility and Hematopoietic SystemModerator: Amanda La GrecaEyal RobenshtokLaura Boucai6:10 PM – 7:10 PMATA Business Meeting (For active and senior ATA members only) 89th ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION® FRIDAY, NOVEMBER 1, 20196:00 AM – 5:30 PMATA Registration Open 6:00 AM – 5:00 PMATA Media Room (Open to press/media only) 6:00 AM – 5:00 PMATA Speaker Ready Room (Open to meeting faculty only) 6:30 AM – 7:45 AMATA Early Riser Symposium: Cutting Edge Concepts in the Surgical Management of Thyroid Disease: The Future is Here (First-come, first served; light breakfast offered beginning at 6:00 AM; session begins at 6:30 AM)Moderator: Jonathon O. RussellIntraoperative Imaging for Parathyroid Gland PreservationTransoral Thyroid Surgery: State of Affairs 2019RFA for Thyroid Nodules and Thyroid Cancer: Pipedream or Disruptive Technology?Nerve Monitoring in Remote Access Surgery: Why It's an ImperativeJonathon O. RussellRalph P. TufanoLeonardo G. RangelHoon Yub Kim8:00 AM – 8:05 AMMorning AnnouncementsAntonio Di CristofanoMona M. Sabra8:05 AM – 8:50 AMATA Plenary Lecture: Pregnancy – A Unique Immunological and Microbial ConditionIntroduction by Terry F. DaviesGil Mor8:50 AM – 10:05 AMBasic/ Translational Abstracts: AutoimmunityCo-Chairs: Michele Marino and Yaron TomerOral Abstract 18: Selective TSH Receptor Signaling by a Novel Small MoleculeOral Abstract 19: Rapamycin Effectively Ameliorates Collagen and Lipid Deposition of the Graves' Ophthalmopathy In BALB/C MiceOral Abstract 20: A Novel Mouse Model of Thyroid Autoimmunity Highlights a Key Role for CCl21 and CD40Oral Abstract 21: A Novel Long-Term Graves' Disease Animal Model Confirmed By Functional Thyrotropin Receptor AntibodiesOral Abstract 22: Rescue of Thyrocytes from Apoptosis Via Activation of AutophagyRauf LatifMeng ZhangLarissa Costa FaustinoTanja DianaSyed Morshed8:50 AM – 10:05 AMClinical Abstracts: Autoimmunity & Thyroid ImagingCo-Chairs: Salvatore Benvenga and Leonidas DuntasOral Abstract 23: A Novel Anti-Cd40 Monoclonal Antibody, Iscalimab, for Control of Graves' HyperthyroidismOral Abstract 24: WITHDRAWNOral Abstract 25: Immunotherapy-associated Thyroid Disorders: Comparison of the Course of Pre-existing Hypothyroidism Compared with De Novo HypothyroidismOral Abstract 26: Use of Autofluorescence-Based Detection of the Parathyroid Glands during Total Thyroidectomy and Risk of Postoperative Hypocalcemia: Results of the Multicenter Randomized Controlled PARAFLUO TrialOral Abstract 27: AiBx, A Deep Learning Model to Classify Thyroid Ultrasound ImagesGeorge J. KahalyMegan Marie KristanFares BenmiloudJohnson Thomas8:50 AM – 11:45 AMRidgway Trainee Conference: Surgical Considerations in Management of Thyroid Surgery (Open to all trainees)(See Trainees Agenda)10:00 AM – 4:30 PMExhibit and Poster Hall Open (Open at 8:00 AM to poster presenters and exhibitors only) 10:05 AM – 11:00 AMPoster Review Session and Break in the Exhibit Hall 10:05 AM – 11:00 AMThyroSeq Updates: Performance in Hurthle Cell Nodules, Cytology Smears, and Impact on Cost Savings: Expo Theater Presented by CBLPath, a Sonic Healthcare Company (Limited seating; first-come, first served)Bryan R. HaugenSteven HodakYuri Nikiforov11:00 AM – 12:15 PMBasic Symposium: Recent Advances in Thyroid RegenerationChair: Terry F. DaviesDirected Differentiation of IPS CellsA Functional Thyroid Organoid ModelMorphogenesis and Differentiation of the Embryonic ThyroidDarrell N. KottonYoshiyuki SaitoMikael Nilsson11:00 AM – 12:15 PMAutoimmune Thyroid Disease: RCT UpdatesChair: Tim KorevaarGraves' OphthalmopathyAutoimmunity and PregnancyLessons Learned and Pitfalls of Designing RCT for Autoimmune Thyroid DiseaseGeorge J. KahalyKristien BoelaertAnne R. Cappola12:15 PM – 1:30 PMPoster Review Session and Break in the Exhibit Hall/Lunch on your Own 12:30 PM – 1:25 PMLENVIMA®: A First-Line Treatment for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Expo Theater Presented by Eisai, Inc. (Lunch provided, Limited seating; first-come, first served)Bryan McIver12:30 PM – 1:30 PMRidgway Trainee Conference: University of Southern California Thyroid Research Group Fellows Fund Basic Career Tracks Breakout Lunch Session (Open and complimentary to all trainees; Lunch ticket required for meal)(See Trainees Agenda)12:30 PM – 1:30 PMRidgway Trainee Conference: Arthur Bauman Clinical Career Paths Breakout Lunch Session (Open and complimentary to all trainees; Lunch ticket required for meal)(See Trainees Agenda)1:30 PM – 2:15 PMSidney H. Ingbar Award Lecture: Rational Combination Therapies in Advanced Thyroid CancerIntroduction by Michael T. McDermottBryan R. Haugen2:20 PM – 3:35 PMBasic Symposium: Pathogenetic Mechanisms of Autoimmune Thyroid DiseaseChair: Yaron TomerViruses, Cytokines and Chemokines in Graves' DiseaseImmune Surveillance, Thyroid Cancer and ThyroiditisDeveloping Novel Approaches to Antigen Specific Therapy for Autoimmune Thyroid DiseaseAlessandro AntonelliBasil RapoportColin M. Dayan2:20 PM – 3:35 PMClinical Symposium: Thyroid CancerChair: Sara AhmadiLow Risk DTC Patients: Who to Treat and Who to WatchLocal Therapy (Laser, RF, MW, ETOH) for Recurrent Nodal DTCTVDT as Predictor of Prognosis and Treatment Response in Metastatic DTCNeoadjuvant Therapy in Advanced Thyroid CancerWendy SacksEnrico PapiniMona M. SabraMaria E. Cabanillas2:20 PM – 3:50 PMRidgway Trainee Conference: Case Discussions – Thyroid Function (Open to all trainees)(See Trainees Agenda)3:35 PM – 4:00 PMBreak in the Exhibit Hall 4:00 PM – 4:45 PMATA Research Grants SessionCo-Chairs: Melanie Goldfarb and Carmelo NuceraProteomic Led Discovery of Essential Genes in Medullary Thyroid CancerA New Molecular Switch in Thyroid CancerDe novo Triiodothyronine (T3) Formation in T3 Toxicosis of Graves' DiseaseWayne O. MilesVicki Emma SmithCintia Eliana Citterio4:50 PM – 5:40 PMDiscussion-Debates/Meet the Professor Workshops (First-come, first-served) 4:50 PM – 5:40 PMDD/MTP 7: Controversies in Identifying RAI Refractory Thyroid CancerGilbert H. DanielsDouglas Van Nostrand4:50 PM – 5:40 PMDD/MTP 8: Molecular Testing of Indeterminate Thyroid NodulesModerator: Stephanie A. FishOscar LinJennifer A. SiposLindsay A. Bischoff4:50 PM – 5:40 PMDD/MTP 9: Side Effects of Immune Checkpoint InhibitorsBhavana KondaRamona Dadu4:50 PM – 5:40 PMDD/MTP 10: Surgical Management of Inherited Medullary Thyroid CancerElizabeth Gardner GrubbsHerbert Chen4:50 PM – 5:40 PMDD/MTP 11: Graves' Disease Panel DiscussionModerator: George J. KahalyLuigi BartalenaTerry J. SmithMichael C. Singer4:50 PM – 5:40 PMDD/MTP 12: Thyroid and PregnancyErik K. AlexanderAlex S. Stagnaro-Green7:30 PM – 9:30 PMATA Annual Banquet (Ticketed event, pre-registration required)ATA Presentation of Awards2019 Distinguished Service Award2019 John B. Stanbury Thyroid Pathophysiology MedalRobert C. SmallridgeSissy M. Jhiang9:30 PM – 11:00 PMATA Leadership SocialATA President Elizabeth N. Pearce invites all meeting attendees to gather for an evening of music, dancing and networking 89th ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION® SATURDAY, NOVEMBER 2, 20196:00 AM – 5:30 PMATA Registration Open 6:00 AM – 5:00 PMATA Media Room (Open to press/media only) 6:00 AM – 5:00 PMATA Speaker Ready Room (Open to meeting faculty only) 6:00 AM – 7:45 PMRidgway Trainee Conference Early Riser Symposium: Thyroid Eye Disease Overview (Open to trainees only; light breakfast offered with ticket beginning at 6:00 AM; session begins at 6:30 AM)Moderator: J. Woody SistrunkGeorge J. KahalyChrysoula DosiouMarius Stan7:30 AM – 9:00 AMBoard of Directors 2019–2020 Meeting(By invitation only; for newly elected and continuing Board members only)Gold Coast, Lobby Level 38:00 AM – 8:05 AMMorning AnnouncementsAntonio Di CristofanoMona M. Sabra8:05 AM – 8:50 AMPlenary Lecture: CART Cell Therapy in Blood MalignanciesIntroduction by Bryan R. HaugenTerry Fry8:50 AM – 10:05 AMShort Call Basic/ Translational Oral AbstractsChair: Whitney S. GoldnerShort Call Oral Abstract 1: Distinct Cytokine Signatures in Anti-PD-1 or Anti-CLTA-4 Induced Thyroiditis: Insights from a New Mouse ModelShort Call Oral Abstract 2: Prognostic Role of Pre-Surgical Circulating Tumoral DNA by NGS in Patients Affected by Medullary Thyroid CarcinomaShort Call Oral Abstract 3: TERT-promoter Mutation Induces Aggression in BRAF(V600E) in Papillary Thyroid Cancer: A Problem of Widespread Immune SuppressionShort Call Oral Abstract 4: Thyrocyte-Specific Absence of Monocarboxylate Transporter (Mct) 8 Does Not Cause Papillary Thyroid Hyperplasia but Alters Intra-Thyroidal Thyroid Hormone MetabolismShort Call Oral Abstract 5: The Thyroid Hormone Receptor Coactivator, MED1, Regulates Hepatic Autophagy and Fatty Acid MetabolismSilvia IppolitoRaffaele CiampiAna-Maria ChindrisEva Katrin WirthPaul M. Yen8:50 AM – 10:05 AMShort Call Clinical Oral AbstractsChair: Kepal PatelShort Call Oral Abstract 6: The Risk of Acute Pancreatitis is Increased in Users of Antithyroid Drugs, but Differs Between Methiamazol and Propylthiouracil: Evidence from a Nationwide Case-Crossover StudyShort Call Oral Abstract 7: Tall Cell Component in Papillary Thyroid Carcinoma and its Relation with Tumor Aggressiveness: Analysis of 3133 Consecutive CasesShort Call Oral Abstract 8: Clinical Outcomes in a Phase 2 Trial of Apatinib in Chinese Patients with Progressive Radioiodine Refractory Differentiated Thyroid CancerShort Call Oral Abstract 9: Revolutionizing the Therapeutic Landscape of a Deadly DiseaseShort Call Oral Abstract 10: Redifferentiation Radioiodine (RAI)-Therapy in Patients with Metastatic Papillary, Follicular and Poorly Differentiated Thyroid CancerLaszlo HegedusFulvio BasoloYan-Song LinAnastasios ManiakasRosa Falcone8:50 AM – 11:00 AMPediatric Thyroid Forum Satellite Symposium 2019: Update on Pediatric Thyroid Disease(See Pediatric Thyroid Forum Agenda)10:00 AM – 1:30 PMExhibit and Poster Hall Open (Open at 8:00 AM to poster presenters and exhibitors only) 10:05 AM – 11:00 AMPoster Review Session and Break in the Exhibit Hall 10:05 AM – 11:00 AMHow the Novel Levothyroxine Sodium Oral Solution Provides Alternative Management Strategies for Hypothyroidism: Expo Theater Presented by IBSA Pharma Inc. (Limited seating; first-come, first served)Leonard WartofskyFrancesco S. CeliErnest O. AsamoahCharles A. Carter11:00 AM – 11:45 AMLewis E. Braverman Award Lecture: From Mentee to Mentor…What I Have Learned in 25 YearsIntroduction by Emad KandilMartha A. Zeiger11:45 AM – 1:00 PMPoster Review Session and Break in the Exhibit Hall/Lunch on your Own 12:00 PM – 12:55 PMVITRAKVI® (larotrectinib) UPDATE: CLINICAL EFFICACY, SAFETY, AND CASE PRESENTATIONS: Expo Theater Presented by Bayer (Lunch provided, Limited seating; first-come, first served)Lori J. Wirth12:00 PM – 1:00 PMRidgway Trainee Conference: All Trainees Lunch Session – How to Get Your Work Published (Open and complimentary to all trainees; Lunch ticket required for meal)(See Trainees Agenda)1:00 PM – 2:15 PMArthur Bauman Clinical Symposium: Anaplastic Thyroid Cancer GuidelinesChair: Bryan R. HaugenEthical Considerations in Anaplastic Thyroid CancerSurgical ConsiderationsMedical ConsiderationsM. Sara RosenthalElectron KebebewKeith C. Bible1:30 PM –Exhibit and Poster Hall Closes 2:00 PM – 4:00 PMATA Alliance for Patient Education Free Public Forum (Open to the general public and all meeting attendees)Sponsored by the ATA Alliance members: American Thyroid Association, Bite Me Cancer, Graves' Disease and Thyroid Foundation, Light of Life Foundation, MCT8 – AHDS Foundation, ThyCa: Thyroid Cancer Survivors' Association, Thyroid Cancer Alliance, Thyroid Cancer Canada and Thyroid Federation International 2:15 PM – 2:30 PMBreak 2:30 PM – 4:00 PMBasic/ Translational Abstracts: Thyroid CancerCo-Chairs: Christine Spitzweg and Nikita PozdeyevOral Abstract 28: Characterization of Allele-Specific Promoter Methylation and Transcription Factor Binding in Thyroid Cancer Cell Lines with the Activating TERT Promoter MutationOral Abstract 29: Direct BAX Activation Effectively Induces Apoptosis in Anaplastic Thyroid Cancer CellsOral Abstract 30: The Proto-Oncogene PBF Mediates Src Modulation of Radioiodine UptakeBrittany Avin McKelveyXhesika Shanja-GrabarzMohammed Merae Alshahrani, II Oral Abstract 31: Tumor Hypoxia as a Therapeutic Target and a Prognostic Indicator in Dedifferentiated Thyroid CancerOral Abstract 32: Emergence of Resistance-Associated Mutations of RET V804M and KRAS in Medullary Thyroid Carcinoma (MTC) Patients Treated with Tyrosine Kinase Inhibitors (TKI) Cabozantinib and VandetanibOral Abstract 33: BRAFV600Eoverrides NOTCH Signaling in Thyroid CancerBen MaMimi HuRoch-Philippe Charles2:30 PM – 4:00 PMClinical Abstracts: Thyroid CancerCo-Chairs: Gregory W. Randolph and Juan P. Brito CampanaOral Abstract 34: Diagnostic Accuracy of Fine Needle Aspiration Cytology in Pediatric Thyroid Nodules based on Bethesda ClassificationOral Abstract 35: Management of Thyroid Nodules in Children and Adolescents Based on the Japanese Guidelines for Thyroid Nodules: The Fukushima Health Management SurveyOral Abstract 36: Natural History and Outcomes of Observation for Papillary Thyroid Carcinoma after Lobectomy with Single or Multiple Indications for Completion Total ThyroidectomyOral Abstract 37: National Trends and Outcomes from Thyroidectomy Performed for Thyroid Cancer via Alternative Access Techniques: A National Cancer Database AnalysisOral Abstract 38: A Multicenter Prospective Study of Lateral Neck Lymph Node Mapping in Papillary Thyroid Carcinoma Using Carbon NanoparticlesOral Abstract 39: Evidence for Existence of Two Histological and Molecular Types of Poorly Differentiated Thyroid CarcinomaWen JiangHiroki ShimuraSiyuan XuElizabeth LancasterNai-si HuangAlyaksandr Nikitski4:05 PM – 5:20 PMBasic Symposium: Novel Targets for Thyroid Cancer – What's in the Pipeline?Chair: Carmelo NuceraMethodology, Criteria, and Characterization of Thyroid Cancer Patient-Derived Tumor XenograftsCyclin-Dependent Kinase Inhibitors in Thyroid CancerTargeting SRC in Thyroid CancerJohn Al Copland, IIIEunkyung LeeRebecca E. Schweppe4:05 PM – 5:20 PMSurgical Management of Difficult Multinodular Goiters: International PerspectivesModerators: Herbert Chen and Jan L. KasperbauerThyroid Surgery By Flashlight: Situations in Low-Resource EnvironmentsThoracotomy in Substernal Goiter Always Necessary? Fact or Fiction?Minimizing Nervousness About the Nerve: Preservation and Monitoring in Goiter SurgeryThere Are No Difficult Patients – Only Difficult Patient InteractionsKristin LongJuan Pablo PantojaCatherine F. SinclairJulie Miller5:25 PM – 6:40 PMSymposium in Memory of Leslie J. De GrootCo-Chairs: Samuel Refetoff and James A. FaginThyroid ManagerThyroid CancerAutoimmune Thyroid Disease: Interaction between TSAb and the TSH ReceptorThyroid Hormone Action: Effect on Development and the BrainPeter A. KoppFurio PaciniBasil RapoportJuan Bernal89th ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION® SUNDAY, NOVEMBER 3, 20196:30 AM – 11:30 AMATA Registration Open 6:30 AM – 11:15 AMEvidence Based Use of T3 + T4 Combinations: London, UK and Chicago, IL, USA, A Joint ETA/BTA/ATA Symposium (First-come, first served; light breakfast offered beginning at 6:30 AM; session begins at 7:00 AM)(See ETA/BTA/ATA Symposium Agenda)9:00 AM – 11:30 AMThyroid Cancer Tumor Board SessionModerator: Mimi HuEndocrinologySurgeryNuclear MedicineMedical OncologyRadiation OncologyGilbert H. DanielsChristopher D. RaeburnSophie LeboulleuxManisha H. ShahJames D. Brierley11:15 AM89th Annual Meeting of the ATA Concludes Thursday, October 31, 2019Highlighted Oral 1Thyroid Cancer Thursday Highlighted Oral TranslationalATTENUATION OF CTNNB1 INHIBITS PROGRESSION OF BRAFV600E‐INDUCED PAPILLARY THYROID CANCER AND PROMOTES RE‐DIFFERENTIATION AND IODINE UPTAKEM. Zou, H. BinEssa, Y. Al‐Malki, I. Al‐Jammaz, A. Al‐Enezi, F. Al‐Mohanna, A. Assiri, B. Meyer, A. Alzahrani, Y. ShiKing Faisal Specialist Hospital and Research Centre, Riyadh, Saudi ArabiaBRAFV600E mutation is the most frequent genetic alteration in papillary thyroid cancer (PTC) and is the main driver in the tumorigenesis of PTC through constitutive activation of MAPK signaling pathway. β‐catenin (encoded by CTNNB1) is a key downstream component of canonical Wnt signaling pathway and is often overexpressed in PTC or mutated in anaplastic thyroid cancer. BRAFV600E‐driven tumors have been speculated to rely on Wnt/β‐catenin signaling to sustain its growth and progression, although the details of this interaction remain to be determined. The current study investigated the role of β‐catenin in BrafV600E‐driven thyroid cancer in a genetically engineered mouse model. Two genetically engineered mouse strains were used: LSL‐BrafV600E and LSL‐Ctnnb1null. These two conditional BrafV600E knock‐in and Ctnnb1 knockout mice were bred with TPO‐Cre mice to produce thyroid‐specific expression of BrafV600ECtnnb1null (BVE‐Ctnnb1null) and BrafV600ECtnnb1wt (BVE‐Ctnnb1wt) strains, respectively. Thyroid tumor progression and survival were evaluated in BVE‐Ctnnb1nulland BVE‐Ctnnb1wt mice. Overexpression of Ctnnb1 was observed in thyroid tumors from BVE‐Ctnnb1wt mice. Following Ctnnb1 knockout, thyroid tumors became more localized with evidence of re‐differentiation into follicular architecture. The overall survival of BVE‐Ctnnb1null mice was increased by more than 50% during 13‐month observation (p < 0.001, n = 20). Mechanistically, this phenotype was associated with down‐regulation of MAPK, PI3K/Akt, and epithelial‐mesenchymal transition, and increased expression of E‐cadherin and genes for thyroid hormone synthesis such as Tg, Tpo, Tshr, and Slc5a5 (sodium‐iodide symporter). Slc5a5 was the most impacted gene by Ctnnb1 knockout with 18‐fold increase in RNA expression in thyroid tumors. PET/CT scan demonstrated significantly higher thyroid uptake of I124 in BVE‐Ctnnb1null mice than BVE‐Ctnnb1wt mice. Our results indicate that Wnt/β‐catenin pathway plays an important role in BrafV600E‐mediated thyroid cancer progression. Inhibition of Ctnnb1 partially restores iodine uptake in thyroid cancer cells. Targeting Ctnnb1 may have significant benefit for radioactive iodine‐refractory thyroid cancer.Highlighted Oral 2Autoimmunity Thursday Highlighted Oral ClinicalEFFICACY OF TEPROTUMUMAB, AN INSULIN‐LIKE GROWTH FACTOR‐1 RECEPTOR ANTAGONIST ANTIBODY, IN PATIENTS WITH ACTIVE THYROID EYE DISEASE: POOLED RESULTS FROM TWO PLACEBO‐CONTROLLED TRIALSG.J. Kahaly1, T.J. Smith2, S. Sile3, E.H. Thompson3, T. Vescio3, R. Perdok3, J.W. Sherman3, R.S. Douglas41Johannes Gutenberg University Medical Center, Mainz, Germany; 2University of Michigan Kellogg Eye Center, Ann Arbor, MI; 3Horizon Pharma USA, Inc., Lake Forest, IL; 4Cedars Sinai Medical Center, Los Angeles, CAActive thyroid eye disease (TED) is a debilitating autoimmune disorder characterized by inflammation and proptosis along with significantly altered quality of life (QoL) including appearance and vision changes. Herein we report pooled efficacy results from the Phase 2 and 3 studies of teprotumumab. The 24‐week randomized, double‐masked, placebo‐controlled, parallel‐group, multicenter, Phase 2 (NCT01868997) and Phase 3 (NCT03298867) studies were conducted in adults with active, moderate‐to‐severe TED. Patients (pts) with recent onset of TED (<9 months) were treated with teprotumumab or placebo every 3 weeks for a total of eight infusions. Primary and secondary endpoint data were pooled.171 pts were included in the pooled intent‐to‐treat analyses (84 teprotumumab, 87 placebo). The demographics (teprotumumab versus placebo) were as follows: mean age of 51.5 years versus 51.4, 69% female versus 77%, and 76% non‐smokers versus 70%. More teprotumumab pts had reductions in proptosis of ≥2 mm (65/84 [77.4%] versus 13/87 [14.9%], p < 0.001), and an overall response (% of pts meeting proptosis and clinical activity score, CAS outcome) (62/84 [73.8%] versus 12/87 [13.8%], p < 0.001) at week 24. The reduction in average change from baseline through week 24 in proptosis, was greater in pts who received teprotumumab (‐2.63 mm) than in those who received placebo (‐0.31 mm, p < 0.001). The % of pts with absent TED activity (CAS of 0 or 1) was greater with teprotumumab at week 24 (52/84 [61.9%] versus 19/87 [21.8%], p < 0.001). The diplopia responder rate (% pts improved 1 or more grades) was higher with teprotumumab (69.7%) versus placebo (30.5%; p < 0.001) in those with baseline diplopia (66 and 59 pts, respectively). Improvements in average chan
Referência(s)